BG-C9074 + tislelizumab

BG-C9074 + tislelizumab is a combination investigational therapy being studied in early-phase clinical trials for advanced solid tumors. **BG-C9074** is an antibody-drug conjugate (ADC) that targets the immune checkpoint protein **B7H4** (V-set domain-containing T-cell activation inhibitor 1, VTCN1), a molecule overexpressed in various cancers and associated with immune evasion. BG-C9074 is designed to selectively deliver a cytotoxic payload to B7H4-expressing tumor cells, inducing cell death. **Tislelizumab** is a humanized IgG4 monoclonal antibody targeting **programmed cell death protein 1 (PD-1)**, a checkpoint inhibitor that blocks negative immune regulation, thereby enhancing antitumor immune responses. The combination aims to exploit both tumor-targeted cytotoxicity (via BG-C9074) and immune reactivation (via tislelizumab) for synergistic anticancer effects. As of 2025, this regimen is being evaluated in first-in-human Phase 1 trials for patients with advanced or metastatic solid tumors[1][3][5][9].

Other names

BG-C9074 + tislelizumab